CAMBRIDGE, Mass., May 5 /PRNewswire-FirstCall/ -- Millennium Pharmaceuticals, Inc. today announced that its presentation at the Robert W. Baird & Co. 2005 Growth Stock Conference will be webcast live and may be accessed by visiting the Investors section of the Company’s website, http://www.millennium.com/.
(Photo: http://www.newscom.com/cgi-bin/prnh/19991220/MLNMLOGO )
Millennium management will provide an overview of the Company and upcoming corporate events. The presentation will be delivered at 11:50 a.m. EDT on Thursday, May 12, 2005 from the Four Seasons Hotel in Chicago. The presentation will be archived for 30 days.
About Millennium
Millennium Pharmaceuticals, Inc., a leading biopharmaceutical company based in Cambridge, Mass., markets VELCADE(R) (bortezomib) for Injection, a novel cancer product, co-promotes INTEGRILIN(R) (eptifibatide) Injection, a market-leading cardiovascular product, and has a robust clinical development pipeline of product candidates. The Company’s research, development and commercialization activities are focused in three therapeutic areas: oncology, cardiovascular, and inflammation. By applying its knowledge of the human genome, its understanding of disease mechanisms, and its industrialized drug discovery platform, Millennium is seeking to develop breakthrough products.
Editors’ Note: This press release is also available under the Media section of the Company’s website at: http://www.millennium.com/.
Contact: Kyle Kuvalanka (617) 761-4734
Photo: NewsCom: http://www.newscom.com/cgi-bin/prnh/19991220/MLNMLOGOAP Archive: http://photoarchive.ap.org/PRN Photo Desk, photodesk@prnewswire.comMillennium Pharmaceuticals, Inc.
CONTACT: Kyle Kuvalanka of Millennium Pharmaceuticals, Inc., +1-617-761-4734
Web site: http://www.millennium.com/
Company News On-Call: http://www.prnewswire.com/comp/114562.html
